Completed PHASE1 INTERVENTIONAL 1-arm NCT00675831

Infusion of Donor Lymphocytes Depleted of CD25+ Regulatory T-cells in Patients With Relapsed Hematologic Malignancies

Infusion of Donor Lymphocytes Depleted of CD25+ Regulatory T-cells in Patients With Relapsed Hematologic Malignancies After Matched Allogeneic Hematopoietic Stem Cell Transplantation

Sponsor: Dana-Farber Cancer Institute

Conditions Hematologic Malignancies

Interventions CliniMACS CD25 Reagent Device

Updated 8 times since 2017 Last updated: Sep 28, 2016 Started: Dec 31, 2007 Primary completion: Jan 31, 2013 Completion: Jan 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Hematologic Malignancies and is currently completed. Dana-Farber Cancer Institute leads this study, which shows 8 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Aug 2020 — Jan 2021 [monthly]

Completed PHASE1
Feb 2020 — Aug 2020 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jun 2018 — Feb 2020 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Dec 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dana-Farber Cancer Institute
Miltenyi Biomedicine GmbH

Data source: Dana-Farber Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States